Drug Discovery - Pre-clinical Studies

ImmunityBio’s hAd5 vaccine candidate for Covid-19 succeeds in preclinical study

ImmunityBio said that its human Ad5 vaccine candidate (hAd5 vaccine candidate), which is being developed for the prevention of Covid-19, has yielded positive preclinical results.

Catalent, Ennaid Therapeutics collaborate to develop antiviral treatment for Covid-19 disease

Catalent has collaborated with speciality pharmaceutical company Ennaid Therapeutics for the development of an oral and antiviral treatment for Covid-19 disease.

Vir, Alnylam to develop VIR-2703 RNAi therapeutic candidate for Covid-19 treatment

Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).

Hoth Therapeutics announces agreement to joint development for a self-assembling vaccine (SAV) for the potential prevention of coronavirus

Hoth Therapeutics has reached an agreement with Voltron Therapeutics to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects to prevent the Coronavirus (COVID-19) based upon VaxCelerate.

RedHill Biopharma secures FDA approval for Talicia to treat H pylori infection in adults

Israeli biopharmaceutical firm RedHill Biopharma has secured the US Food and Drug Administration (FDA) approval for Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Neoleukin Therapeutics, Aquinox Pharmaceuticals complete merger transaction

Neoleukin Therapeutics, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals.

Knopp reports positive preclinical data for neonatal epilepsy drug candidate

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida.

Study suggests epigenetic protein as new therapeutic target in AML

A new study in the UK has shown that EZH2, an epigenetic protein, can potentially be a new therapeutic target for the treatment of acute myeloid leukemia (AML).

Redx says in vivo data indicates potential of ROCK2 in fibrosis treatment

UK based biotech company Redx said that its lead selective ROCK2 compound has been shown to have broad potential in the treatment of fibrosis as per new in vivo data.